Advances in Antihypertensive Therapy: Mechanisms and Evidence-Based Insights

Mohamad-Ali Salloum, PharmD • November 16, 2025

Share

  • Slide title

    Write your caption here
    Button

  • Slide title

    Write your caption here
    Button

  • Slide title

    Write your caption here
    Button

  • Slide title

    Write your caption here
    Button

Evidence-based hypertension insights Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide. Effective management relies on pharmacological interventions that target distinct physiological pathways. Below is a concise, scientifically rigorous overview of three cornerstone classes—ACE inhibitors, CCBs, and ARBs—followed by recent evidence and a quick self‑test.

Blood Vessel “Tone” at a Glance

Vasoconstriction versus vasodilation Narrow vessel indicates higher resistance and afterload. Wide vessel indicates lower resistance and afterload. Vasoconstriction ↑R Vasodilation ↓R Higher afterload Lower afterload

ACE Inhibitors

ACE inhibitors block conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone-mediated sodium retention. Net effects: arterial vasodilation, ↓ systemic vascular resistance, and favorable renal/cardiovascular outcomes—especially in diabetes and chronic kidney disease.

ACE inhibitor mechanism in the RAAS pathway Renin converts angiotensinogen to angiotensin I. ACE is blocked so angiotensin II formation falls, reducing vasoconstriction and aldosterone. Renin Angiotensin I Angiotensin II ACE ↓ Vasoconstriction & aldosterone
↓ SVR Renoprotection DM/CKD benefit

Calcium Channel Blockers (CCBs)

CCBs inhibit L‑type calcium channels in vascular smooth muscle (and, for non‑dihydropyridines, in myocardium). Results: arterial vasodilation, ↓ myocardial contractility, and lower cardiac workload. Dihydropyridines are predominantly vascular; non‑dihydropyridines also reduce heart rate.

Calcium Channel Blocker mechanism L-type calcium channel on smooth muscle membrane is blocked, reducing calcium influx and causing vasodilation. Smooth muscle membrane L‑type CCB blocks channel → ↓ Ca²⁺ Arterial vasodilation & ↓ afterload
DHP: vascular Non‑DHP: HR ↓ Afterload ↓

Angiotensin II Receptor Blockers (ARBs)

ARBs selectively antagonize AT 1 receptors, preventing angiotensin II–mediated vasoconstriction and aldosterone release. Downstream: improved arterial compliance and reduced afterload. Often favored when ACE inhibitors are not tolerated.

ARB blockade of AT1 receptor Angiotensin II attempts to bind the AT1 receptor but ARB prevents binding, reducing vasoconstriction and aldosterone. AT1 Angiotensin II ARB ↓ Vasoconstriction & ↓ Aldosterone
Afterload ↓ Tolerability ↑

Recent Evidence & Meta‑Analyses (2022–2025)

Network meta‑analysis (2025): efficacy and combinations

A 2025 network meta‑analysis synthesizing 88 RCTs (n=487,076) found that ACE inhibitors, ARBs, and CCBs significantly reduce stroke and all‑cause mortality versus placebo. Combination therapy with an ACE inhibitor + CCB provided superior protection against stroke and cardiovascular mortality compared with monotherapy (Yu et al., PLOS One, 2025).

Reference: Yu D, et al. PLOS One (2025).

STEP post‑hoc (2025): exposure time and outcomes

In a STEP trial analysis, longer exposure to ARBs and CCBs was associated with ~45% and ~30% reductions, respectively, in composite cardiovascular outcomes, with neutral effects for diuretics and higher risk signals with β‑blockers (likely confounding by indication).

Reference: Peng X, et al. BMC Medicine (2025).

CKD‑focused synthesis (2025): BP control and renoprotection

Recent systematic reviews in CKD indicate ACE inhibitors/ARBs reduce proteinuria and slow CKD progression, while CCBs remain effective for blood pressure control—supporting tailored regimens in proteinuric disease.

Reference: Singh A, et al. Cureus (2025).

Clinical take‑home: current guidelines favor individualized therapy based on comorbidities and risk. Combination therapy—particularly ACE inhibitor + CCB—has robust support for enhanced cardiovascular protection.

Clinical Implications

  • ACE inhibitors for patients with diabetes/CKD or those needing renoprotection.
  • CCBs(dihydropyridines) for potent vasodilation; consider non‑DHPs when HR control is also desired.
  • ARBs as alternatives when ACE inhibitors are not tolerated; strong outcome data support their use.
  • Combination therapy(ACEi + CCB) is frequently superior to monotherapy for vascular outcomes.

At‑a‑Glance: Class Effects

  • Vasodilation → ↓ afterload, ↓ blood pressure, improved flow.
  • Neurohormonal modulation (RAAS) → ↓ aldosterone, ↓ sodium retention.
  • Myocardial effects (non‑DHP CCBs) → ↓ HR/contractility.
Visual guide: relative emphasis of vascular vs. myocardial effects.

Quick Quiz: Test Your Knowledge

1) Which class directly blocks AT 1 receptors?

a) ACE inhibitors
b) ARBs
c) Dihydropyridine CCBs

2) A primary effect of dihydropyridine CCBs is:

a) Reduced renin release
b) Direct negative chronotropy in all cases
c) Arterial vasodilation via L‑type channel blockade

3) Which combination has strong evidence for superior stroke and CV protection vs monotherapy?

a) ACE inhibitor + CCB
b) ARB + β‑blocker
c) Loop diuretic + thiazide

4) In proteinuric CKD, first‑line preference often favors:

a) ACE inhibitor/ARB for renoprotection
b) Non‑DHP CCB only
c) Any agent; no differences ever observed

Sources: Yu D, et al. PLOS One (2025); Peng X, et al. BMC Medicine (2025); Singh A, et al. Cureus (2025).

References:

- Yu D et al. Comparative efficacy of antihypertensive drug classes for stroke prevention: A network meta-analysis. PLOS One. 2025.
- Peng X et al. Impact of antihypertensive drug classes on cardiovascular outcomes: Insights from the STEP study. BMC Medicine. 2025.
- Singh A et al. Comparative efficacy and safety of ACE inhibitors, ARBs, and CCBs in CKD patients. Cureus. 2025. 

List of Services

    • Slide title

      Write your caption here
      Button

    • Slide title

      Write your caption here
      Button

    • Slide title

      Write your caption here
      Button

    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    Understanding Root Cause Analysis: The 5 Whys and Fishbone method

    By Mohamad-Ali Salloum, PharmD • February 10, 2026
    Learn 5 Whys and Fishbone (Ishikawa) for Root Cause Analysis in clinical research, with practical examples and an interactive quiz—no fluff, just clarity.

    Understanding CAPA in Clinical Trials: A Practical Guide for CRAs

    By Mohamad-Ali Salloum, PharmD • February 9, 2026
    A clear, practical guide to CAPA for Clinical Research Associates—covering corrective and preventive actions, real‑world scenarios, and an interactive quiz to reinforce learning.

    30 Minutes That Can Change Your Life: The Science Behind a Morning Walk

    By Mohamad-Ali Salloum, PharmD • February 5, 2026
    Boost your health with a simple 30‑minute morning walk backed by science—better heart health, mood, sleep, and energy.

    The 5 AM Club Review— What I Learned, What I Kept, and What I’d Do Differently

    By Mohamad-Ali Salloum, PharmD • February 4, 2026

    The Wink You Can't Control: Why Your Eyelid Won't Stop Twitching

    By Mohamad-Ali Salloum, PharmD • February 3, 2026
    References: Gunes IB, Gunes A. Association Between Eyelid Twitching and Digital Screen Time, Uncorrected Refractive Error, Intraocular Pressure, and Blood Electrolyte Imbalances. Cureus . 2024;16(9):e69249. Available from: https://www.cureus.com/articles/291035-association-between-eyelid-twitching-and-digital-screen-time-uncorrected-refractive-error-intraocular-pressure-and-blood-electrolyte-imbalances Banik R, Miller NR. Chronic myokymia limited to the eyelid is a benign condition. J Neuroophthalmol . 2004;24(4):290–2. Available from: https://scholars.mssm.edu/en/publications/chronic-myokymia-limited-to-the-eyelid-is-a-benign-condition-2 Hallett M. Blepharospasm: recent advances. Neurology . 2002;59(11):1759–60. Available from: https://europepmc.org/abstract/MED/12434791 Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord . 2002;17(1):7–12. Available from: https://europepmc.org/article/MED/11835433 Zeppieri M, Ameer MA, Jahngir MU, Patel BC. Meige Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://europepmc.org/article/MED/30020730 Zhang Y, Adamec I, Habek M. Superior oblique myokymia: a meta-analysis. J Ophthalmol . 2018;2018:7290547. Available from: https://doi.org/10.1155/2018/7290547 Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev . 2020;11:CD004900. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004900.pub2/abstract Khalkhali M. Topiramate-induced persistent eyelid myokymia. Case Rep Psychiatry . 2016;2016:7901085. Available from: https://europepmc.org/articles/PMC4886081/

    Sleep: The Secret Performance Drug You're Probably Not Using Enough

    By Mohamad-Ali Salloum, PharmD • February 1, 2026
    References: Sen A, Tai XY. Sleep duration and executive function in adults. Curr Neurol Neurosci Rep. 2023;23:801–813. [link.springer.com] Nature Research Intelligence. Sleep deprivation and cognitive performance. Nature Portfolio. 2023. Available from: https://www.nature.com/… [nature.com] Skourti E, Simos P, Zampetakis A, et al. Long-term associations between objective sleep and verbal memory performance. Front Neurosci. 2023;17:1265016. [frontiersin.org] Hauglund NL, Andersen M, Tokarska K, et al. Norepinephrine‑mediated slow vasomotion drives glymphatic clearance during sleep. Cell. 2025;188(3):606‑622.e17. [cell.com] Shirolapov IV, Zakharov AV, Smirnova DA, et al. The role of the glymphatic clearance system in sleep–wake interactions and neurodegeneration. Neurosci Behav Physiol. 2024;54:199–204. [link.springer.com] Kong Y, Yu B, Guan G, et al. Effects of sleep deprivation on sports performance: a systematic review and meta-analysis. Front Physiol. 2025;16:1544286. [frontiersin.org] Gong M, Sun M, Sun Y, et al. Effects of acute sleep deprivation on sporting performance in athletes. Nat Sci Sleep. 2024;16:—. [tandfonline.com] Dean B, Hartmann T, Wingfield G, et al. Sleep restriction between consecutive days of exercise impairs cycling performance. J Sleep Res. 2023;32(3):e13857. [onlinelibr....wiley.com] Mah CD, Mah KE, Kezirian EJ, Dement WC. The effects of sleep extension on athletic performance in collegiate basketball players. Sleep. 2011;34(7):943–950. [psycnet.apa.org] Cunha LA, Costa JA, Marques EA, et al. Impact of sleep interventions on athletic performance: a systematic review. Sports Med Open. 2023;9:58. [link.springer.com] Teece AR, Beaven CM, Argus CK, et al. Daytime naps improve afternoon power and perceptual measures in elite rugby union athletes. Sleep. 2023;46(12):zsad133. [academic.oup.com] Mesas AE, Núñez de Arenas-Arroyo S, Martinez-Vizcaino V, et al. Daytime napping and cognitive/physical sport performance: meta-analysis of RCTs. Br J Sports Med. 2023;57(7):417–27. [bjsm.bmj.com] Haines Roberts SS, Teo WP, Warmington SA. Effects of training and competition on the sleep of elite athletes. Br J Sports Med. 2019;53(8):513–522. [bjsm.bmj.com] Walsh NP, Halson SL, Sargent C, et al. Sleep and the athlete: 2021 expert consensus recommendations. Br J Sports Med. 2021;55(7):356–368. [bjsm.bmj.com] Janse van Rensburg DC, Fowler PM, Racinais S. Practical tips to manage travel fatigue and jet lag in athletes. Br J Sports Med. 2021;55(15):821–822. [bjsm.bmj.com] Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: AASM/SRS consensus statement. Sleep. 2015;38(6):843–844. [aasm.org] Centers for Disease Control and Prevention. FastStats: Sleep in adults. CDC. 2024. Available from: https://www.cdc.gov/sleep/… [cdc.gov]

    Put the Screens to Bed Before You Do: Why the Last 30-60 Minutes Matter (And What to Do Instead)

    By Mohamad-Ali Salloum, PharmD • January 30, 2026
    References: Gooley JJ, Chamberlain K, Smith KA, et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab. 2011;96(3):E463‑E472. [academic.oup.com] Chang AM, Aeschbach D, Duffy JF, Czeisler CA. Evening use of light‑emitting eReaders negatively affects sleep, circadian timing, and next‑morning alertness. Proc Natl Acad Sci USA. 2015;112(4):1232‑1237. [hms.harvard.edu] Schöllhorn I, Stefani O, Lucas RJ, et al. Melanopic irradiance defines the impact of evening display light on sleep latency, melatonin and alertness. Commun Biol. 2023;6:1090. [nature.com] He J‑W, Tu Z‑H, Xiao L, Su T, Tang Y‑X. Effect of restricting bedtime mobile phone use on sleep, arousal, mood, and working memory: A randomized pilot trial. PLoS One. 2020;15(2):e0228756. [journals.plos.org] Hartstein LE, Mathew GM, Reichenberger DA, et al. The impact of screen use on sleep health across the lifespan: a National Sleep Foundation consensus statement. Sleep Health. 2024;10(4):373‑384. [sleephealt…ournal.org] Höhn C, Hahn MA, Gruber G, et al. Effects of evening smartphone use on sleep and declarative memory consolidation in male adolescents and young adults. Brain Commun. 2024;6(3):fcae173. Finucane E, O’Brien A, Treweek S, et al. Does reading a book in bed make a difference to sleep? The People’s Trial—an online, pragmatic randomized trial. Trials. 2021;22:873. [link.springer.com] Ong JC, Manber R, Segal Z, Xia Y, Shapiro S, Wyatt JK. A randomized controlled trial of mindfulness meditation for chronic insomnia. Sleep. 2014;37(9):1553‑1563. [academic.oup.com] , [mindfulchair.com] He X, Pan B, Ma N, et al. The association of screen time and the risk of sleep outcomes: a systematic review and meta‑analysis. Front Psychiatry. 2025;16:1640263. Shechter A, Quispe KA, Mizhquiri Barbecho JS, et al. Interventions to reduce short‑wavelength light at night and their effects on sleep: systematic review and meta‑analysis. SLEEP Advances. 2020;1(1):zpaa002. [academic.oup.com]

    The Science of Habit Tracking: How Tiny Daily Actions Transform Your Health, Performance, and Life

    By Mohamad-Ali Salloum, PharmD • January 29, 2026
    References: Harkin B, Webb TL, Chang BPI, Prestwich A, Conner M, Kellar I, et al. Does monitoring goal progress promote goal attainment? A meta-analysis of the experimental evidence. Psychol Bull . 2016;142(2):198–229. Available from: https://www.apa.org/pubs/journals/releases/bul-bul0000025.pdf Compernolle S, DeSmet A, Poppe L, Crombez G, De Bourdeaudhuij I, Cardon G, et al. Effectiveness of interventions using self-monitoring to reduce sedentary behavior in adults: a systematic review and meta-analysis. Int J Behav Nutr Phys Act . 2019;16(1):63. Available from: https://link.springer.com/article/10.1186/s12966-019-0824-3 Patel ML, Brooks TL, Bennett GG. Consistent self‑monitoring in a commercial app‑based intervention for weight loss: results from a randomized trial. J Behav Med . 2020;43:391–401. Available from: https://link.springer.com/article/10.1007/s10865-019-00091-8 Patel ML, Hopkins CM, Brooks TL, Bennett GG. Comparing self-monitoring strategies for weight loss in a smartphone app: randomized controlled trial. JMIR Mhealth Uhealth . 2019;7(2):e12209. Available from: https://mhealth.jmir.org/2019/2/e12209/ Lally P, Van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. Available from: https://repositorio.ispa.pt/bitstream/10400.12/3364/1/IJSP_998-1009.pdf Singh B, Murphy A, Maher C, Smith AE. Time to form a habit: A systematic review and meta-analysis of health behaviour habit formation and its determinants. Healthcare (Basel) . 2024;12(23):2488. Available from: https://www.mdpi.com/2227-9032/12/23/2488 Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: A meta‑analysis of effects and processes. In: Advances in Experimental Social Psychology . 2006;38:69–119. Available from: https://www.researchgate.net/publication/37367696 Adriaanse MA, Gollwitzer PM, De Ridder DTD, De Wit JBF, Kroese FM. Breaking habits with implementation intentions: A test of underlying processes. Pers Soc Psychol Bull . 2011;37(4):502–13. Available from: https://dspace.library.uu.nl/bitstream/handle/1874/380229/0146167211399102.pdf Palmer CA, Bower JL, Cho KW, Clementi MA, Lau S, Oosterhoff B, et al. Sleep loss and emotion: A systematic review and meta-analysis of over 50 years of experimental research. Psychol Bull . 2023;149(11):2314–48. Available from: https://www.apa.org/pubs/journals/releases/bul-bul0000410.pdf Kong Y, Yu B, Guan G, Wang Y, He H. Effects of sleep deprivation on sports performance and perceived exertion in athletes and non-athletes: a systematic review and meta-analysis. Front Physiol . 2025;16:1544286. Available from: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1544286/full Tadros M, Newby JM, Li S, Werner‑Seidler A. Psychological treatments to improve sleep quality in university students: systematic review and meta-analysis. PLoS One . 2025;20(2):e0317125. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317125 Locke EA, Latham GP. Building a practically useful theory of goal setting and task motivation: A 35‑year odyssey. Am Psychol . 2002;57(9):705–17. Available from: https://med.stanford.edu/content/dam/sm/s-spire/documents/PD.locke-and-latham-retrospective_Paper.pdf

    GCP R2 vs. GCP R3: What Really Changed — and Why CRAs Are the Heroes of the Transition

    By Mohamad-Ali Salloum, PharmD • January 16, 2026
    Reference: ACRP. “ICH E6(R2) to ICH E6(R3) Comparison.” (Jan 28, 2025) — terminology & essential records: PDF Clinical Trials Toolkit. “Summary of Key Changes in ICH E6(R3).” (Mar 25, 2025) — proportionality, QbD, safety reporting: Article PharmaEduCenter. “Key changes between ICH GCP E6 R3 and E6 R2.” (Aug 10, 2025) — structure & glossary: Blog CITI Program. “Navigating the Transition from ICH E6(R2) to ICH E6(R3).” (Mar 12, 2025) — consent & site practices: Blog IntuitionLabs. “ICH E6 (R3) Explained.” (Updated Jan 13, 2026) — rationale, data governance: Deep dive

    How Clinical Research Associates Can Stay Compliant With HIPAA & HITECH

    By Mohamad-Ali Salloum, PharmD • January 16, 2026
    More Posts